trial · primary record
rozanolixizumab
Generalized Myasthenia Gravis
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 14 |
| Primary completion | 2026-10-05 |
| Primary endpoint | Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) Visit |
| Registry ID | NCT06149559 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:53.908Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06149559
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.